Investigational drug · Phase 2
Acmopatide
Also called: CT-868, RO7795074
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight, Obese, Type 1 Diabetes Mellitus.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Acmopatide"
First trial start
2023
Nov 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Acmopatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight
- Obese
- Type 1 Diabetes Mellitus
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Acmopatide" as an intervention, largest first.
- A Study of CT-868 in Type 1 Diabetes MellitusPivotal-lookingCompleted
Carmot Therapeutics, Inc.Industry
NCT06062069 · 111 participants · Start Nov 27, 2023 · Primary completion Jul 7, 2025
Drug: CT-868; CT-868 Pen Injector, Placebo · For: Overweight; Obese; Type 1 Diabetes Mellitus
Sites: Concord, California; Escondido, California; Aurora, Colorado · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.
Klein KR, Pettus J, Sonnenberg GE, et al. · Diabetes Care 2026
- Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.
Chakravarthy MV, Elliott MA, Acosta L, et al. · Diabetes Obes Metab 2026
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
Jepsen MM, Christensen MB · Expert Opin Emerg Drugs 2021
Also in development for Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.